<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02631824</url>
  </required_header>
  <id_info>
    <org_study_id>HIPFX-001-AUGM</org_study_id>
    <nct_id>NCT02631824</nct_id>
  </id_info>
  <brief_title>Radiologic and Clinical Outcomes of Augmentation in Fragility Intertrochanteric Hip Fracture Treatment</brief_title>
  <acronym>AFIF</acronym>
  <official_title>Radiologic and Clinical Outcomes of Augmentation in Fragility Intertrochanteric Hip Fracture Treatment: A Randomized Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Infantil Universitario de San Jose</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundación Santa Fe de Bogota</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Infantil Universitario de San Jose</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial to assess if the use of augmentation in the treatment of fragility
      intertrochanteric hip fractures improves radiologic and clinical outcomes in patients aged 65
      years or older 1 year after surgery
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if the use of augmentation with PMMA in the treatment of fragility
      intertrochanteric hip fractures improves radiologic and clinical outcomes in osteoporotic
      patients, investigators aim to conduct a multicentered, randomized, single-blinded clinical
      trial.

      All patients aged 65 years or older arriving to the emergency department of two level-1
      trauma centers in Bogotá, Colombia; Hospital Universitario Fundación Santa Fe de Bogotá and
      Hospital Infantil Universitario de San José, after sustaining a fragility intertrochanteric
      hip fracture that requires open reduction and internal fixation (ORIF) will be included.
      These patients must be willing to accept a 1-year follow-up and are required to sign an
      informed consent agreeing to their participation in the study. For the sample calculation a
      two-tailed analysis with an alpha-level of significance of 0.05, a power of 80% (β = 0.2) was
      performed. A total of 35 patients per group plus a 30% increase to control for loss of
      follow-up was calculated. This gives a total of 90 patients; 45 patients per group.

      Patients meeting inclusion and exclusion criteria will be recruited by convenience sampling
      as they arrive to the emergency department.

      Once included in the study, patients will be stratified by age into two groups: patients aged
      between 65-85 years and patients over 85 years. Then, by using a block randomization, the
      intervention (augmentation) will be randomly allocated in order to divide the sample
      population into an intervention group (ORIF + augmentation with PMMA) and a control group
      (ORIF without augmentation). Randomization will be carried out by the program &quot;Sealed
      Envelope&quot; (https://www.sealedenvelope.com) that generates a list with codes (each code
      representing one patient) and randomly assigns them to either the intervention or the control
      group. This list will be in custody of a research assistant who will not have any contact
      with patients during the trial's duration and will be in charge of writing the allocation of
      each code into a sealed, opaque envelope. Each envelope will be given to the surgeon during
      the procedure at the precise moment where augmentation is needed, revealing whether or not
      augmentation should be performed. Medical care will be based on Orthogeriatric Programs and
      surgeries will be performed by orthopaedic surgeons with a clinical fellowship in Orthopaedic
      Trauma. Patients will be blinded to treatment and will be seen on follow-up visits 15 days,
      one month, 3 months, 6 months, and 12 months after the procedure.

      The primary outcome will be the change in TAD measurement 1 year after the surgical
      procedure. The functional differences between both groups will be measured as secondary
      outcomes. Outcomes (primary and secondary) will be measured during follow-up visits one
      month, 3 months, 6 months, and 12 months after the procedure.

      Results will be analyzed using STATA ® Data Analysis and Statistical Software, version 13.1.
      The sample's demographic and baseline characteristics will be described using descriptive
      statistics. Continuous variables will be reported as arithmetic means while categorical
      variables will be reported as absolute values of frequencies and distribution. For the
      inferential analysis of the results, a Shapiro Wilk W-Test will be used to determine
      normality distribution of values. If normality assumptions are met, the change in TAD
      measurement will be analyzed with a student t-test. If not, its non-parametric analogue
      (Mann-Whitney U-test) will be used. For all other categorical variables, a X2 or Fisher's
      exact test will be used.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TAD measurement</measure>
    <time_frame>immediate postoperative hip x-ray (starting point), at one month, 3 months, 6 months, and 12 months after the procedure.</time_frame>
    <description>The TAD will be measured in the immediate postoperative hip x-ray, one month, 3 months, 6 months, and 12 months after the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parker Mobility Score</measure>
    <time_frame>one month, 3 months, 6 months, and 12 months after the procedure.</time_frame>
    <description>determine the pre-injury level of mobility and evaluate the functional recovery during the follow-up period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D Questionnaire</measure>
    <time_frame>one month, 3 months, 6 months, and 12 months after the procedure.</time_frame>
    <description>determine the health-related quality of life perceived by the patient, both before the injury and during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Visual Analogue Scale</measure>
    <time_frame>one month, 3 months, 6 months, and 12 months after the procedure.</time_frame>
    <description>subjective evaluation of pain intensity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hip Fractures</condition>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>open reduction and internal fixation TFNA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open reduction and internal fixation TFNA Augmentation (Cement)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>open reduction and internal fixation</intervention_name>
    <description>Open reduction and internal fixation using an intramedullary nail</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>Augmentation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TFNA</intervention_name>
    <description>Trochanteric Femoral Nail Advance</description>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_label>Augmentation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Augmentation (Cement)</intervention_name>
    <description>Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).</description>
    <arm_group_label>Augmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients arriving to the emergency department after sustaining a fragility hip
             fracture

          -  radiographic diagnosis of intertrochanteric fracture requiring open reduction and
             internal fixation

          -  patient willing to accept a 1-year follow-up

          -  signature of informed consent

        Exclusion Criteria:

          -  polytrauma

          -  patients with a non-fragility hip fracture (high-energy trauma)

          -  hip fractures due to primary or metastatic tumours,

          -  open or periprosthetic hip fractures

          -  patients with history of organ transplantation and patients with severe dementia.

          -  patients with iatrogenic perforation into the hip joint during procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos M Olarte, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Orthopaedic Department at Hospital Infantil de San José</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniela Sanchez, MD</last_name>
    <phone>573108621670</phone>
    <email>danielasanchez1989@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carlos M Olarte, MD</last_name>
    <phone>573158546947</phone>
    <email>cmolarte@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fundación Santa Fe de Bogotá</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Sanchez, MD</last_name>
      <phone>573108621670</phone>
      <email>danielasanchez1989@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Rodrigo F Pesantez, MD</last_name>
      <phone>573106883199</phone>
      <email>rpesantez@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rodrigo F Pesantez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos M Olarte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Sanchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel A Farfan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rodrigo Jaramillo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julian Salavarrieta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sebastian Suarez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Tafur, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil de San José</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Sanchez, MD</last_name>
      <phone>573108621670</phone>
      <email>danielasanchez1989@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Carlos M Olarte, MD</last_name>
      <phone>573158546947</phone>
      <email>cmolarte@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos M Olarte, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniela Sanchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Quintero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>https://sealedenvelope.com/simple-randomiser/v1/trials/augmentation-in-fragility-intertrochanteric-hip-fracture-treatment</url>
    <description>link for performing randomization</description>
  </link>
  <reference>
    <citation>Kammerlander C, Erhart S, Doshi H, Gosch M, Blauth M. Principles of osteoporotic fracture treatment. Best Pract Res Clin Rheumatol. 2013 Dec;27(6):757-69. doi: 10.1016/j.berh.2014.02.005. Review.</citation>
    <PMID>24836334</PMID>
  </reference>
  <reference>
    <citation>Simunovic N, Devereaux PJ, Sprague S, Guyatt GH, Schemitsch E, Debeer J, Bhandari M. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010 Oct 19;182(15):1609-16. doi: 10.1503/cmaj.092220. Epub 2010 Sep 13. Review.</citation>
    <PMID>20837683</PMID>
  </reference>
  <reference>
    <citation>Friedman SM, Mendelson DA, Kates SL, McCann RM. Geriatric co-management of proximal femur fractures: total quality management and protocol-driven care result in better outcomes for a frail patient population. J Am Geriatr Soc. 2008 Jul;56(7):1349-56. doi: 10.1111/j.1532-5415.2008.01770.x. Epub 2008 May 22.</citation>
    <PMID>18503520</PMID>
  </reference>
  <reference>
    <citation>Cooper C, Campion G, Melton LJ 3rd. Hip fractures in the elderly: a world-wide projection. Osteoporos Int. 1992 Nov;2(6):285-9.</citation>
    <PMID>1421796</PMID>
  </reference>
  <reference>
    <citation>Giannoudis PV, Schneider E. Principles of fixation of osteoporotic fractures. J Bone Joint Surg Br. 2006 Oct;88(10):1272-8. Review.</citation>
    <PMID>17012413</PMID>
  </reference>
  <reference>
    <citation>Moroni A, Larsson S, Hoang Kim A, Gelsomini L, Giannoudis PV. Can we improve fixation and outcomes? Use of bone substitutes. J Orthop Trauma. 2009 Jul;23(6):422-5. doi: 10.1097/BOT.0b013e3181771426. Review.</citation>
    <PMID>19550228</PMID>
  </reference>
  <reference>
    <citation>Kammerlander C, Gebhard F, Meier C, Lenich A, Linhart W, Clasbrummel B, Neubauer-Gartzke T, Garcia-Alonso M, Pavelka T, Blauth M. Standardised cement augmentation of the PFNA using a perforated blade: A new technique and preliminary clinical results. A prospective multicentre trial. Injury. 2011 Dec;42(12):1484-90. doi: 10.1016/j.injury.2011.07.010. Epub 2011 Aug 19.</citation>
    <PMID>21855063</PMID>
  </reference>
  <reference>
    <citation>Kammerlander C, Doshi H, Gebhard F, Scola A, Meier C, Linhart W, Garcia-Alonso M, Nistal J, Blauth M. Long-term results of the augmented PFNA: a prospective multicenter trial. Arch Orthop Trauma Surg. 2014 Mar;134(3):343-9. doi: 10.1007/s00402-013-1902-7. Epub 2013 Dec 3.</citation>
    <PMID>24297215</PMID>
  </reference>
  <reference>
    <citation>Sermon A, Hofmann-Fliri L, Richards RG, Flamaing J, Windolf M. Cement augmentation of hip implants in osteoporotic bone: how much cement is needed and where should it go? J Orthop Res. 2014 Mar;32(3):362-8. doi: 10.1002/jor.22522. Epub 2013 Nov 20.</citation>
    <PMID>24259367</PMID>
  </reference>
  <reference>
    <citation>Eriksson F, Mattsson P, Larsson S. The effect of augmentation with resorbable or conventional bone cement on the holding strength for femoral neck fracture devices. J Orthop Trauma. 2002 May;16(5):302-10.</citation>
    <PMID>11972072</PMID>
  </reference>
  <reference>
    <citation>Augat P, Rapp S, Claes L. A modified hip screw incorporating injected cement for the fixation of osteoporotic trochanteric fractures. J Orthop Trauma. 2002 May;16(5):311-6.</citation>
    <PMID>11972073</PMID>
  </reference>
  <reference>
    <citation>Mattsson P, Larsson S. Unstable trochanteric fractures augmented with calcium phosphate cement. A prospective randomized study using radiostereometry to measure fracture stability. Scand J Surg. 2004;93(3):223-8.</citation>
    <PMID>15544079</PMID>
  </reference>
  <reference>
    <citation>Lee PC, Hsieh PH, Chou YC, Wu CC, Chen WJ. Dynamic hip screws for unstable intertrochanteric fractures in elderly patients--encouraging results with a cement augmentation technique. J Trauma. 2010 Apr;68(4):954-64. doi: 10.1097/TA.0b013e3181c995ec.</citation>
    <PMID>20386288</PMID>
  </reference>
  <reference>
    <citation>Dall'Oca C, Maluta T, Moscolo A, Lavini F, Bartolozzi P. Cement augmentation of intertrochanteric fractures stabilised with intramedullary nailing. Injury. 2010 Nov;41(11):1150-5. doi: 10.1016/j.injury.2010.09.026. Epub 2010 Oct 6.</citation>
    <PMID>20932521</PMID>
  </reference>
  <reference>
    <citation>Baumgaertner MR, Solberg BD. Awareness of tip-apex distance reduces failure of fixation of trochanteric fractures of the hip. J Bone Joint Surg Br. 1997 Nov;79(6):969-71.</citation>
    <PMID>9393914</PMID>
  </reference>
  <reference>
    <citation>Rubio-Avila J, Madden K, Simunovic N, Bhandari M. Tip to apex distance in femoral intertrochanteric fractures: a systematic review. J Orthop Sci. 2013 Jul;18(4):592-8. doi: 10.1007/s00776-013-0402-5. Epub 2013 May 2. Review.</citation>
    <PMID>23636573</PMID>
  </reference>
  <reference>
    <citation>DiMaio FR. The science of bone cement: a historical review. Orthopedics. 2002 Dec;25(12):1399-407; quiz 1408-9. Review.</citation>
    <PMID>12502206</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2015</study_first_submitted>
  <study_first_submitted_qc>December 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2015</study_first_posted>
  <last_update_submitted>September 11, 2016</last_update_submitted>
  <last_update_submitted_qc>September 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Infantil Universitario de San Jose</investigator_affiliation>
    <investigator_full_name>Carlos Mario Olarte</investigator_full_name>
    <investigator_title>Head of Orthopedics Department at HIUSJ</investigator_title>
  </responsible_party>
  <keyword>fragility fractures</keyword>
  <keyword>hip fractures</keyword>
  <keyword>augmentation</keyword>
  <keyword>tip-apex distance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

